Pulmonary Vascular Resistance

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress.

SAN DIEGO — Among patients with pulmonary arterial hypertension, seralutinib lowered pulmonary vascular resistance over 72 weeks, according to research presented at the American Thoracic Society International Conference.

The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

WASHINGTON — In adults with pulmonary arterial hypertension, seralutinib reduced pulmonary vascular resistance over 24 weeks, according to a presentation at the American Thoracic Society International Conference.

Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European Respiratory Journal.

In the phase 2 ARROW trial, selonsertib for 24 weeks failed to significantly reduce pulmonary vascular resistance or achieve clinical improvement in patients with pulmonary arterial hypertension.

Sotatercept (Acceleron Pharma) or placebo in adults on background therapy for pulmonary arterial hypertension.

Treatment with sotatercept for 24 weeks resulted in a reduction in pulmonary vascular resistance among patients with pulmonary arterial hypertension therapy, according to results of the PULSAR trial.

New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in patients at risk for pulmonary hypertension undergoing right heart catheterization.

In the phase 2 PULSAR trial, treatment with sotatercept for 24 weeks resulted in greater reduction in pulmonary vascular resistance than placebo in patients with pulmonary arterial hypertension on stable background therapies.